Loading…
Pacira BioSciences, Inc. is projected to rise to $33.07 by 2027, a +38% move from its current price of $24.04. PCRX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $23.60 | $24.05 | $24.51 | +0.05% |
| May 30 | $23.43 | $24.07 | $24.72 | +0.11% |
| May 31 | $23.30 | $24.08 | $24.88 | +0.16% |
| Jun 1 | $23.19 | $24.09 | $25.02 | +0.21% |
| Jun 2 | $23.10 | $24.10 | $25.15 | +0.26% |
| Jun 3 | $23.02 | $24.12 | $25.26 | +0.32% |
| Jun 4 | $22.95 | $24.13 | $25.37 | +0.37% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $22.95 | $24.13 | $25.37 | +0.37% |
| Week 2 | $22.56 | $24.22 | $26.00 | +0.74% |
| Week 3 | $22.28 | $24.31 | $26.51 | +1.11% |
| Week 4 | $22.07 | $24.40 | $26.97 | +1.48% |
| Week 5 | $21.89 | $24.49 | $27.39 | +1.85% |
| Week 6 | $21.73 | $24.58 | $27.79 | +2.23% |
| Week 7 | $21.60 | $24.67 | $28.17 | +2.61% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Pacira BioSciences, Inc. is a healthcare company that develops, manufactures, markets, distributes, and sells non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. Its product lineup includes EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve.
It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals.
The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.
Pacira BioSciences, Inc. trades in the healthcare space and operates with the ticker PCRX. It currently has a market capitalization of $918.77M and is ranked 2594 by size among listed securities.
Its current price is $23.35, reflecting its position in a niche of non-opioid pain management and regenerative health solutions. The stock presents a mixed near-term outlook, with a forecast that begins near current levels in 2026 and moves higher in subsequent years. The multi-year view shows expanding upside into the late 2020s and beyond, suggesting a substantial potential path of appreciation relative to today’s price.
A major floor 20.3% below — a decisive break under it would weaken the trend.
The nearest floor, 7.2% below — buyers have tended to step in here.
The nearest ceiling, 6.3% above — a clean break opens room to run.
A major ceiling 13.2% above — clearing it would confirm fresh momentum.
Key PCRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PCRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $23.65 | Buy | $23.71 | Buy |
| MA 10 | $23.22 | Buy | $23.51 | Buy |
| MA 20 | $23.64 | Buy | $23.57 | Buy |
| MA 50 | $23.58 | Buy | $23.51 | Buy |
| MA 100 | $22.85 | Buy | $23.40 | Buy |
| MA 200 | $23.72 | Buy | $23.45 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 53.86 | Neutral |
| Stoch RSI (14) | 84.19 | Sell |
| CCI (20) | 35.46 | Neutral |
| Williams %R (14) | -15.61 | Info |
| MACD (12,26,9) | 0.07 | Buy |
| ROC (12) | 3.84 | Buy |
| Bollinger %B (20,2) | 0.61 | Neutral |
| Stochastic %K (14) | 84.39 | Sell |
| TRIX (15) | -0.11 | Sell |
| Awesome (5,34) | -0.34 | Sell |
| Ultimate (7,14,28) | 64.51 | Neutral |
| Momentum (10) | 1.20 | Buy |
| Aroon Osc (25) | -64.00 | Sell |
| Hull MA (9) | 24.18 | Sell |
| ADX (14) | 13.52 | Neutral |
| ATR (14) | 0.44 | Info |
The near-term technical picture for Pacira BioSciences, Inc. is neutral. The RSI14 sits at 50, and the 50-day simple moving average is $23.53 while the 200-day simple moving average is $23.72.
Support is identified at $22.31 and resistance at $25.55, framing a 30-day range between $20.75 and $26.28. Overall volatility over the last year is elevated, with annualized volatility listed at 30, underscoring a cautious short-term stance for traders.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $19.16 | $24.04 | $33.67 | 0% | Neutral | |
| $27.01 | $33.07 | $42.40 | +38% | Bullish | |
| $30.19 | $37.65 | $49.54 | +57% | Bullish | |
| $32.96 | $41.73 | $56.06 | +74% | Bullish | |
| $35.23 | $45.21 | $61.80 | +88% | Bullish | |
| $39.60 | $51.43 | $71.42 | +114% | Bullish | |
| $50.53 | $66.37 | $93.46 | +176% | Bullish | |
| $55.70 | $73.92 | $105.44 | +207% | Bullish | |
| $57.91 | $77.62 | $112.02 | +223% | Bullish | |
| $62.76 | $84.92 | $123.92 | +253% | Bullish | |
| $100.08 | $141.26 | $216.02 | +488% | Bullish | |
| $193.93 | $293.69 | $481.43 | +11.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $19.16 | $24.04 | $28.13 | +0.00% |
| June 2026 | $20.76 | $24.22 | $28.81 | +0.75% |
| July 2026 | $21.49 | $25.22 | $30.28 | +4.12% |
| August 2026 | $22.19 | $26.16 | $31.64 | +3.74% |
| September 2026 | $22.08 | $26.12 | $31.78 | -0.15% |
| October 2026 | $22.11 | $26.25 | $32.11 | +0.48% |
| November 2026 | $22.70 | $27.04 | $33.23 | +2.99% |
| December 2026 | $22.84 | $27.27 | $33.67 | +0.88% |
Click any year to see its month-by-month PCRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Pacira BioSciences, Inc.'s 2026 outlook centres on $24.04, within a $19.16 to $33.67 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, PCRX could reach as high as $42.40, with a base case around $33.07 and support toward $27.01 — roughly +38% from $24.04. Buyers look set to stay in control over this stretch.
Expect PCRX to range from $30.19 to $49.54 through 2028. The $37.65 average target implies a +57% move from current prices. That is up +14% on the projected 2027 average. Momentum favours further upside here.
The PCRX price prediction for 2029 points to an average of $41.73 (low $32.96, high $56.06) — a potential gain of +74% on today's $24.04. Buyers look set to stay in control over this stretch.
In 2030, PCRX is projected to trade between $35.23 and $61.80, averaging $45.21 — a potential gain of +88% from today's $24.04. That is up +8% on the projected 2029 average. Momentum favours further upside here.
Pacira BioSciences, Inc.'s 2031 outlook centres on $51.43, within a $39.60 to $71.42 range. That is up +14% on the projected 2030 average. That marks a +114% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, PCRX could reach as high as $93.46, with a base case around $66.37 and support toward $50.53 — roughly +176% from $24.04. Momentum favours further upside here.
Expect PCRX to range from $55.70 to $105.44 through 2033. The $73.92 average target implies a +207% move from current prices. That is up +11% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The PCRX price prediction for 2034 points to an average of $77.62 (low $57.91, high $112.02) — a potential gain of +223% on today's $24.04. Momentum favours further upside here.
In 2035, PCRX is projected to trade between $62.76 and $123.92, averaging $84.92 — a potential gain of +253% from today's $24.04. That is up +9% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Pacira BioSciences, Inc.'s 2040 outlook centres on $141.26, within a $100.08 to $216.02 range. That is up +66% on the projected 2035 average. That marks a +488% change versus current levels. Momentum favours further upside here.
By 2050, PCRX could reach as high as $481.43, with a base case around $293.69 and support toward $193.93 — roughly +11.2x from $24.04. Buyers look set to stay in control over this stretch.
Investing $1,000 in PCRX today (≈ 41.597338 PCRX) could be worth
$12,216.74
+$11,216.74 (+1122%) by 2050 · US Dollar
Based on the average projected PCRX price of $293.69 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PCRXwould be worth at today's price.
$1,000 invested in PCRX on May 27, 2025 (≈ 38.729667 PCRX) would be worth
$931.06
-$68.94 (-6.9%) today · 0.93× · US Dollar
Based on a PCRX entry price of $25.82 vs. today's $24.04.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $23 | $1,045.22 | +4.5% |
| 1 month ago | $25.55 | $940.9 | -5.9% |
| 3 months ago | $22.59 | $1,064.19 | +6.4% |
| 6 months ago | $23.57 | $1,019.94 | +2.0% |
| 1 year ago | $25.82 | $931.06 | -6.9% |
| All time (5.0y) ago | $62.61 | $383.96 | -61.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PCRX forecast.
Our base-case forecast reaches $48.00 around 2031.
Implied market cap at $48.00: $1.89B
The multi-year forecast points to a bullish trend beginning in 2027, with the avg price rising from $31.62 (2027) and a min of $25.82 to a max of $40.53, supported by a 35.4 (ROIPct) backdrop and a bullish sentiment. By 2030, the avg is $41.65 with a max of $56.90, and an ROIPct of 78.4, indicating meaningful upside from today’s level. The outlook strengthens further into the 2030s, with 2040 showing an avg of $122.60 and a max of $187.23, accompanied by an ROIPct of 425.1 and a bullish sentiment.
By 2050, the avg price reaches $246.60 with a max of $403.54 and an ROIPct of 956.1, maintaining a bullish stance. Across these years, the forecast underscores a steady path of appreciation from a 2026 baseline near today’s price, with notable upside potential in the longer term. These numbers are estimates and not guarantees, and involve uncertainty and risk that could alter outcomes.
Tap a question to reveal the answer.
In 2030, the forecasted avg price is $41.65, with a min of $32.48 and a max of $56.90. The associated ROIPct is 78.4 and the sentiment is BULLISH.
The forecast shows a bullish trend from 2027 onward, with rising averages and positive ROIPct values through 2050, indicating upside potential relative to today’s price, though these are estimates and not guarantees.
Yes. The forecast projects higher price levels in the coming years, with the 2035 max at $109.33, the 2040 max at $187.23, and the 2050 max at $403.54, suggesting the potential to exceed $100.
For 2026, the forecast shows an avg price of $23.35, a min of $19.16, and a max of $32.39, with an ROIPct of 0 and sentiment NEUTRAL.
The 2040 forecasted avg price is $122.60, with a min of $86.98 and a max of $187.23, and an ROIPct of 425.1, with a bullish sentiment.
Pacira BioSciences, Inc. Community Discussion
0Share your Pacira BioSciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.